#BEGIN_DRUGCARD DB00149

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Hard Body BCAA (MLO Products) (L-Leucine + L-Isoleucine + L-Valine)
Hi-Test Muscle Octane BCAA's (Anabol Naturals) (L-Leucine + L-Isoleucine + L-Valine)

# Brand_Names:
Not Available

# CAS_Registry_Number:
61-90-5

# ChEBI_ID:
15603

# Chemical_Formula:
C6H13NO2

# Chemical_IUPAC_Name:
(2S)-2-amino-4-methylpentanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An essential branched-chain amino acid important for hemoglobin formation. [PubChem]

# Dosage_Forms:
Capsule	Oral
Powder	Oral
Tablet	Oral

# Drug_Category:
Dietary supplement
Essential Amino Acids
Micronutrient

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.52

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2.15E+004 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Leucine

# HET_ID:
LEU

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1

# InChI_Key:
InChIKey=ROHFNLRQFUQHCH-YFKPBYRVSA-N

# Indication:
Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
149

# Mechanism_Of_Action:
This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.

# Melting_Point:
293 °C

# Molecular_Weight_Avg:
131.1729

# Molecular_Weight_Mono:
131.094628665

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1OBC

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/bra_0042.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450197

# Pharmacology:
An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine

# Predicted_LogP_Hydrophobicity:
-1.8

# Predicted_LogS:
-0.27

# Predicted_Water_Solubility:
6.98e+01 g/l

# Primary_Accession_No:
DB00149

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00033

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)C[C@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(2S)-2-Amino-4-methylpentanoic acid
(S)-(+)-Leucine
(S)-2-Amino-4-methylpentanoic acid
(S)-2-Amino-4-methylvaleric acid
(S)-Leucine
1-Leucine
2-Amino-4-methylpentanoic acid
2-Amino-4-methylvaleric acid
L-(+)-Leucine
L-(-)-2-Amino-4-methylpentanoic acid
L-a-Aminoisocaproic acid
Leu
Leucin
Leucine
alpha-Amino-gamma-methylvaleric acid
alpha-Aminoisocaproic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:08 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/L-Leucine

# pKa_Isoelectric_Point:
2.35 (at 13 °C)

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16774921	Hsu JL, Rho SB, Vannella KM, Martinis SA: Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. J Biol Chem. 2006 Aug 11;281(32):23075-82. Epub 2006 Jun 14.
17095543	Zhu B, Zhao MW, Eriani G, Wang ED: A present-day aminoacyl-tRNA synthetase with ancestral editing properties. RNA. 2007 Jan;13(1):15-21. Epub 2006 Nov 9.
17144674	Ma JJ, Zhao MW, Wang ED: Split leucine-specific domain of leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus. Biochemistry. 2006 Dec 12;45(49):14809-16.
17378584	Lue SW, Kelley SO: A single residue in leucyl-tRNA synthetase affecting amino acid specificity and tRNA aminoacylation. Biochemistry. 2007 Apr 17;46(15):4466-72. Epub 2007 Mar 23.
17407263	Vu MT, Martinis SA: A unique insert of leucyl-tRNA synthetase is required for aminoacylation and not amino acid editing. Biochemistry. 2007 May 1;46(17):5170-6. Epub 2007 Apr 4.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
LARS2

# Drug_Target_1_GenBank_ID_Gene:
D21851

# Drug_Target_1_GenBank_ID_Protein:
40788954

# Drug_Target_1_GeneCard_ID:
LARS2

# Drug_Target_1_Gene_Name:
LARS2

# Drug_Target_1_Gene_Sequence:
>2715 bp
AGAATGGCTTCTGTTTGGCAGAGATTGGGTTTTTATGCCTCTCTTCTGAAAAGACAGCTA
AATGGTGGGCCAGATGTCATCAAGTGGGAAAGGAGAGTAATTCCCGGATGTACCAGAAGC
ATCTACAGTGCCACGGGAAAGTGGACAAAAGAGTATACATTGCAGACAAGAAAGGATGTT
GAGAAATGGTGGCATCAACGAATAAAAGAACAGGCCTCCAAAATTTCAGAAGCTGATAAA
TCGAAGCCAAAATTTTACGTGCTTTCCATGTTCCCTTATCCTTCTGGTAAGCTGCACATG
GGCCATGTGCGTGTCTACACCATCAGCGACACCATAGCACGGTTCCAGAAGATGAGAGGG
ATGCAGGTCATCAACCCCATGGGATGGGATGCTTTTGGATTGCCTGCTGAAAATGCCGCA
GTCGAGAGGAATCTACATCCACAAAGTTGGACACAAAGTAATATTAAACACATGAGGAAA
CAGCTTGATCGTCTGGGCCTGTGTTTCAGCTGGGATAGGGAAATAACTACGTGTTTGCCA
GATTACTACAAGTGGACTCAGTATCTCTTTATTAAACTGTATGAGGCTGGGCTGGCCTAT
CAAAAGGAGGCCCTGGTTAACTGGGACCCAGTGGATCAAACAGTGCTTGCCAATGAGCAG
GTGGATGAACATGGCTGTTCATGGCGTTCTGGAGCAAAGGTGGAACAGAAGTACCTCAGA
CAATGGTTTATTAAGACAACCGCTTATGCAAAGGCCATGCAGGACGCGTTGGCAGACCTT
CCAGAATGGTATGGAATAAAAGGCATGCAAGCCCACTGGATTGGGGACTGTGTGGGCTGC
CACCTGGACTTCACATTAAAGGTTCATGGGCAAGCCACGGGCGAAAAGCTGACTGCCTAT
ACGGCCACCCCTGAAGCCATTTATGGCACCTCCCACGTGGCCATCTCGCCCAGCCACAGA
CTCCTACATGGGCACAGCTCTCTGAAGGAAGCCTTGAGGATGGCCCTTGTCCCTGGCAAA
GATTGCCTCACGCCTGTAATGGCTGTGAACATGCTTACCCAGCAGGAGGTCCCTGTCGTT
ATTTTGGCCAAAGCTGACTTGGAAGGCTCTCTGGATTCAAAAATAGGAATTCCCAGTACT
AGCTCAGAGGACACCATCTTAGCCCAAACCCTGGGCCTGGCCTACTCTGAAGTCATTGAA
ACTTTGCCAGATGGCACAGAGAGACTGAGCAGCTCTGCTGAGTTCACAGGTATGACCCGG
CAGGATGCTTTTCTAGCCCTGACTCAGAAAGCCCGGGGGAAGAGAGTGGGTGGAGACGTG
ACAAGTGATAAACTGAAAGACTGGCTGATTTCACGGCAGCGGTACTGGGGCACACCAATC
CCCATTGTCCACTGCCCAGTCTGTGGCCCCACACCTGTGCCCCTGGAGGACTTGCCTGTG
ACCCTGCCCAACATCGCGTCTTTCACTGGCAAGGGAGGCCCCCCACTGGCCATGGCTTCA
GAGTGGGTGAACTGCTCCTGCCCAAGGTGCAAGGGAGCAGCCAAGAGAGAGACAGACACG
ATGGATACCTTTGTTGATTCTGCTTGGTACTACTTCAGATACACTGACCCTCATAATCCA
CACAGCCCTTTTAACACAGCAGTGGCCGATTACTGGATGCCTGTGGATTTGTACATTGGA
GGGAAAGAACATGCCGTCATGCACTTGTTCTATGCAAGATTCTTTAGTCATTTTTGCCAT
GATCAAAAAATGGTTAAACATAGGGAGCCTTTTCATAAGCTGCTGGCCCAAGGCCTTATC
AAGGGGCAGACATTCCGCCTACCATCTGGACAGTATCTACAGAGAGAGGAAGTGGATCTC
ACAGGTTCCGTTCCTGTTCATGCAAAAACGAAAGAGAAGTTAGAGGTGACGTGGGAGAAG
ATGAGTAAGTCCAAACACAACGGGGTGGACCCAGAGGAAGTTGTGGAGCAGTATGGGATC
GACACGATTCGGCTCTACATCCTTTTTGCTGCCCCTCCTGAGAAGGATATCTTGTGGGAT
GTGAAAACTGATGCTCTCCCTGGGGTGCTGAGATGGCAACAACGACTGTGGACCTTGACA
ACTCGGTTTATTGAGGCCAGGGCTTCTGGGAAGTCTCCCCAGCCTCAGCTGCTGAGTAAC
AAGGAGAAAGCTGAGGCCAGGAAGCTCTGGGAGTACAAGAACTCCGTCATCTCTCAGGTG
ACCACCCATTTCACAGAGGACTTCTCACTGAATTCTGCAATTTCTCAGCTGATGGGACTC
AGCAATGCCCTCTCGCAAGCCTCTCAGAGCGTCATTCTCCACAGCCCCGAGTTTGAGGAT
GCTTTGTGTGCCCTGATGGTAATGGCTGCTCCACTGGCCCCTCATGTAACCTCAGAGATC
TGGGCAGGCCTGGCGCTGGTGCCGAGGAAGCTCTGTGCCCACTACACTTGGGATGCCAGT
GTGCTGCTCCAGGCATGGCCTGCTGTGGACCCGGAGTTCCTGCAGCAGCCTGAGGTTGTC
CAGATGGCAGTTCTGATCAACAATAAAGCTTGTGGCAAAATTCCTGTGCCCCAACAAGTT
GCCCGGGACCAGGACAAAGTCCACGAATTTGTTCTTCAAAGCGAGCTGGGTGTCAGGCTT
TTGCAAGGACGAAGCATCAAGAAGTCCTTCCTTTCCCCGAGAACTGCCCTCATCAACTTC
CTGGTGCAAGATTGA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
7584026	Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res. 1994;1(1):27-35.

# Drug_Target_1_HGNC_ID:
HGNC:17095

# Drug_Target_1_HPRD_ID:
05178

# Drug_Target_1_ID:
227

# Drug_Target_1_Locus:
3p21.3

# Drug_Target_1_Molecular_Weight:
101977

# Drug_Target_1_Name:
Probable leucyl-tRNA synthetase, mitochondrial

# Drug_Target_1_Number_of_Residues:
903

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00133	tRNA-synt_1
PF08264	Anticodon_1

# Drug_Target_1_Protein_Sequence:
>Probable leucyl-tRNA synthetase, mitochondrial precursor
MASVWQRLGFYASLLKRQLNGGPDVIKWERRVIPGCTRSIYSATGKWTKEYTLQTRKDVE
KWWHQRIKEQASKISEADKSKPKFYVLSMFPYPSGKLHMGHVRVYTISDTIARFQKMRGM
QVINPMGWDAFGLPAENAAVERNLHPQSWTQSNIKHMRKQLDRLGLCFSWDREITTCLPD
YYKWTQYLFIKLYEAGLAYQKEALVNWDPVDQTVLANEQVDEHGCSWRSGAKVEQKYLRQ
WFIKTTAYAKAMQDALADLPEWYGIKGMQAHWIGDCVGCHLDFTLKVHGQATGEKLTAYT
ATPEAIYGTSHVAISPSHRLLHGHSSLKEALRMALVPGKDCLTPVMAVNMLTQQEVPVVI
LAKADLEGSLDSKIGIPSTSSEDTILAQTLGLAYSEVIETLPDGTERLSSSAEFTGMTRQ
DAFLALTQKARGKRVGGDVTSDKLKDWLISRQRYWGTPIPIVHCPVCGPTPVPLEDLPVT
LPNIASFTGKGGPPLAMASEWVNCSCPRCKGAAKRETDTMDTFVDSAWYYFRYTDPHNPH
SPFNTAVADYWMPVDLYIGGKEHAVMHLFYARFFSHFCHDQKMVKHREPFHKLLAQGLIK
GQTFRLPSGQYLQREEVDLTGSVPVHAKTKEKLEVTWEKMSKSKHNGVDPEEVVEQYGID
TIRLYILFAAPPEKDILWDVKTDALPGVLRWQQRLWTLTTRFIEARASGKSPQPQLLSNK
EKAEARKLWEYKNSVISQVTTHFTEDFSLNSAISQLMGLSNALSQASQSVILHSPEFEDA
LCALMVMAAPLAPHVTSEIWAGLALVPRKLCAHYTWDASVLLQAWPAVDPEFLQQPEVVQ
MAVLINNKACGKIPVPQQVARDQDKVHEFVLQSELGVRLLQGRSIKKSFLSPRTALINFL
VQD

# Drug_Target_1_Reaction:
ATP + L-leucine + tRNALeu = AMP + diphosphate + L-leucyl-tRNALeu

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q15031

# Drug_Target_1_SwissProt_Name:
SYLM_HUMAN

# Drug_Target_1_Synonyms:
EC 6.1.1.4
LeuRS
Leucine--tRNA ligase
Probable leucyl-tRNA synthetase, mitochondrial precursor

# Drug_Target_1_Theoretical_pI:
8.32

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Isoform A:Mitochondrion. Isoform B:Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
12670965	Berger BJ, English S, Chan G, Knodel MH: Methionine regeneration and aminotransferases in Bacillus subtilis, Bacillus cereus, and Bacillus anthracis. J Bacteriol. 2003 Apr;185(8):2418-31.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
BCAT2

# Drug_Target_2_GenBank_ID_Gene:
U68418

# Drug_Target_2_GenBank_ID_Protein:
2342862

# Drug_Target_2_GeneCard_ID:
BCAT2

# Drug_Target_2_Gene_Name:
BCAT2

# Drug_Target_2_Gene_Sequence:
>1179 bp
ATGGCCGCAGCCGCTCTGGGGCAGATCTGGGCACGAAAGCTTCTCTCTGTCCCTTGGCTT
CTGTGTGGTCCCAGAAGATATGCCTCCTCCAGTTTCAAGGCTGCAGACCTGCAGCTGGAA
ATGACACAGAAGCCTCATAAGAAGCCTGGCCCCGGCGAGCCCCTGGTGTTTGGGAAGACA
TTTACCGACCACATGCTGATGGTGGAATGGAATGACAAGGGCTGGGGCCAGCCCCGAATC
CAGCCCTTCCAGAACCTCACGCTGCACCCAGCCTCCTCCAGCCTCCACTACTCCCTGCAG
CTGTTTGAGGGCATGAAGGCGTTCAAAGGCAAAGACCAGCAGGTGCGCCTCTTCCGCCCC
TGGCTCAACATGGACCGGATGCTGCGCTCAGCCATGCGCCTGTGCCTGCCGAGTTTCGAC
AAGCTGGAGTTGCTGGAGTGCATCCGCCGGCTCATCGAAGTGGACAAGGACTGGGTCCCC
GATGCCGCCGGCACCAGCCTCTATGTGCGGCCTGTGCTCATTGGGAACGAGCCCTCGCTG
GGTGTCAGCCAGCCCAGGCGCGCGCTCCTGTTCGTCATTCTCTGCCCAGTGGGTGCCTAC
TTCCCTGGAGGCTCCGTGACCCCGGTCTCCCTCCTGGCCGACCCAGCCTTCATCCGGGCC
TGGGTGGGCGGGGTCGGCAACTACAAGTTAGGTGGGAATTATGGGCCCACCGTGTTAGTG
CAACAGGAGGCACTCAAGCGGGGCTGTGAACAGGTCCTCTGGCTGTATGGGCCCGACCAC
CAGCTCACCGAGGTGGGAACCATGAACATCTTTGTCTACTGGACCCACGAAGATGGGGTG
CTGGAGCTGGTGACGCCCCCGCTGAATGGTGTTATCCTGCCTGGAGTGGTCAGACAGAGT
CTACTGGACATGGCTCAGACCTGGGGTGAGTTCCGGGTGGTGGAGCGCACGATCACCATG
AAGCAGTTGCTGCGGGCCTTGGAGGAGGGCCGCGTGCGGGAAGTCTTTGGCTCGGGCACC
GCTTGCCAGGTCTGCCCAGTGCACCGAATCCTGTACAAAGACAGGAACCTCCATATTCCC
ACCATGGAAAATGGGCCTGAGCTGATCCTCCGCTTCCAGAAGGAGCTGAAGGAGATCCAG
TACGGAATCAGAGCCCACGAGTGGATGTTCCCGGTGTGA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
11170829	Than NG, Sumegi B, Than GN, Bellyei S, Bohn H: Molecular cloning and characterization of placental tissue protein 18 (PP18a)/human mitochondrial branched-chain aminotransferase (BCATm) and its novel alternatively spliced PP18b variant. Placenta. 2001 Feb-Mar;22(2-3):235-43.
11264579	Yennawar N, Dunbar J, Conway M, Hutson S, Farber G: The structure of human mitochondrial branched-chain aminotransferase. Acta Crystallogr D Biol Crystallogr. 2001 Apr;57(Pt 4):506-15.
12269802	Yennawar NH, Conway ME, Yennawar HP, Farber GK, Hutson SM: Crystal structures of human mitochondrial branched chain aminotransferase reaction intermediates: ketimine and pyridoxamine phosphate forms. Biochemistry. 2002 Oct 1;41(39):11592-601.
8702755	Eden A, Simchen G, Benvenisty N: Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 1996 Aug 23;271(34):20242-5.
9165094	Bledsoe RK, Dawson PA, Hutson SM: Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta. 1997 Apr 25;1339(1):9-13.

# Drug_Target_2_HGNC_ID:
HGNC:977

# Drug_Target_2_HPRD_ID:
00217

# Drug_Target_2_ID:
795

# Drug_Target_2_Locus:
19q13

# Drug_Target_2_Molecular_Weight:
44288

# Drug_Target_2_Name:
Branched-chain-amino-acid aminotransferase, mitochondrial

# Drug_Target_2_Number_of_Residues:
392

# Drug_Target_2_PDB_ID:
1KTA

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_2_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, mitochondrial precursor
MAAAALGQIWARKLLSVPWLLCGPRRYASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKT
FTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRP
WLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSL
GVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLV
QQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQS
LLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIP
TMENGPELILRFQKELKEIQYGIRAHEWMFPV

# Drug_Target_2_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids

# Drug_Target_2_SwissProt_ID:
O15382

# Drug_Target_2_SwissProt_Name:
BCAT2_HUMAN

# Drug_Target_2_Synonyms:
BCAT(m)
Branched-chain-amino-acid aminotransferase, mitochondrial precursor
EC 2.6.1.42
PP18
Placental protein 18

# Drug_Target_2_Theoretical_pI:
8.82

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17077963	Saito M, Nishimura K, Wakabayashi S, Kurihara T, Nagata Y: Purification of branched-chain amino acid aminotransferase from Helicobacter pylori NCTC 11637. Amino Acids. 2007 Sep;33(3):445-9. Epub 2006 Nov 2.
17554170	Chen CD, Huang TF, Lin CH, Guan HH, Hsieh YC, Lin YH, Huang YC, Liu MY, Chang WC, Chen CJ: Purification, crystallization and preliminary X-ray crystallographic analysis of branched-chain aminotransferase from Deinococcus radiodurans. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):492-4. Epub 2007 May 5.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
BCAT1

# Drug_Target_3_GenBank_ID_Gene:
U21551

# Drug_Target_3_GenBank_ID_Protein:
1036780

# Drug_Target_3_GeneCard_ID:
BCAT1

# Drug_Target_3_Gene_Name:
BCAT1

# Drug_Target_3_Gene_Sequence:
>1155 bp
ATGGATTGCAGTAACGGATCGGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTG
GGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCA
GACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGG
TCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCAC
CCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGA
GGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGC
TCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAA
CAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATT
CGTCCTGCATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTG
CTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCAGTG
TCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGGACTGCAAG
ATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGACGTAGATAATGGGTGT
CAGCAGGTCCTGTGGCTCTATGGCAGAGACCATCAGATCACTGAAGTGGGAACTATGAAT
CTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTCCACTAGAT
GGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATCAGTGGGGT
GAATTTAAGGTGTCAGAGAGATACCTCACCATGGATGACTTGACAACAGCCCTGGAGGGG
AACAGAGTGAGAGAGATGTTTAGCTCTGGTACAGCCTGTGTTGTTTGCCCAGTTTCTGAT
ATACTGTACAAAGGCGAGACAATACACATTCCAACTATGGAGAATGGTCCTAAGCTGGCA
AGCCGCATCTTGAGCAAATTAACTGATATCCAGTATGGAAGAGAAGAGAGCGACTGGACA
ATTGTGCTATCCTGA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
8692959	Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N: ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7143-8.

# Drug_Target_3_HGNC_ID:
HGNC:976

# Drug_Target_3_HPRD_ID:
00216

# Drug_Target_3_ID:
574

# Drug_Target_3_Locus:
12pter-q12

# Drug_Target_3_Molecular_Weight:
42953

# Drug_Target_3_Name:
Branched-chain-amino-acid aminotransferase, cytosolic

# Drug_Target_3_Number_of_Residues:
386

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_3_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, cytosolic
MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTV
EWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRM
YRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTK
ALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDN
GCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQ
WGEFKVSERYLTMDDLSTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPK
LASRILSKLTDIQYGREESDWTIVLS

# Drug_Target_3_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine

# Drug_Target_3_SwissProt_ID:
P54687

# Drug_Target_3_SwissProt_Name:
BCAT1_HUMAN

# Drug_Target_3_Synonyms:
BCAT(c)
EC 2.6.1.42
ECA39 protein

# Drug_Target_3_Theoretical_pI:
4.95

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
LCMT2

# Drug_Target_4_GenBank_ID_Gene:
AB011119

# Drug_Target_4_GenBank_ID_Protein:
40788285

# Drug_Target_4_GeneCard_ID:
LCMT2

# Drug_Target_4_Gene_Name:
LCMT2

# Drug_Target_4_Gene_Sequence:
>2091 bp
CAGACTGCCATTCCTGAGTCTCTTCTGGCCATGGGCCCCCGGAGCCGTGAGCGTCGGGCA
GGCGCGGTACAGAACACCAACGACAGCAGCGCCCTCAGCAAGCGTTCCCTGGCCGCGCGC
GGGTACGTGCAGGACCCCTTTGCCGCGTTGCTGGTTCCGGGCGCGGCGCGCCGCGCACCG
CTCATTCACCGAGGCTACTACGTCCGCGCACGCGCCGTGAGGCACTGCGTGCGCGCTTTT
TTGGAGCAGATTGGCGCGCCCCAGGCCGCGCTTCGCGCGCAGATCTTGTCTCTCGGCGCT
GGCTTCGACTCGCTCTATTTTCGCTTAAAAACCGCGGGCCGCCTGGCCCGGGCTGCAGTC
TGGGAGGTGGATTTTCCGGACGTGGCGCGGCGCAAAGCAGAAAGGATTGGAGAGACGCCA
GAGCTGTGCGCGTTAACCGGGCCTTTCGAGAGGGGGGAGCCCGCGTCCGCGCTGTGCTTT
GAGAGCGCAGACTACTGCATCCTGGGTCTGGACTTGCGGCAGCTCCAGCGAGTGGAGGAG
GCCCTGGGCGCCGCGGGGCTCGACGCAGCCTCACCCACTCTGCTCCTGGCCGAGGCGGTG
CTGACCTACCTCGAGCCGGAGAGTGCCGCGGCCCTCATCGCCTGGGCAGCCCAGCGTTTT
CCTAATGCCCTTTTCGTGGTCTATGAGCAGATGAGGCCTCAAGACGCCTTTGGCCAGTTC
ATGCTGCAACATTTTCGGCAGCTAAACTCCCCCCTGCATGGCCTGGAGCGTTTTCCTGAC
GTGGAGGCGCAGCGGCGCCGCTTCCTTCAAGCTGGCTGGACCGCCTGCGGTGCCGTGGAC
ATAAATGAATTCTATCACTGCTTTCTTCCCGCAGAAGAACGCCGGCGGGTGGAAAATATT
GAACCCTTTGACGAATTTGAGGAGTGGCATCTGAAGTGCGCCCATTATTTCATTCTGGCA
GCTTCTAGGGGAGACACCCTCTCCCACACCCTAGTGTTTCCATCCTCAGAGGCATTTCCT
CGCGTAAATCCTGCTTCGCCTTCAGGGGTATTCCCTGCCAGCGTAGTCAGTAGCGAGGGC
CAGGTCCCAAACCTGAAGAGATATGGCCACGCCTCTGTCTTCTTGAGCCCAGACGTTATT
CTCAGTGCAGGAGGATTTGGAGAGCAGGAGGGGCGGCACTGCCGAGTGAGCCAGTTTCAC
TTGCTCTCAAGAGATTGTGACTCTGAATGGAAAGGCAGCCAAATAGGCAGTTGTGGGACT
GGAGTTCAGTGGGATGGACGCCTTTATCACACCATGACAAGACTCTCAGAGAGTCGGGTT
CTGGTTCTGGGAGGGAGACTGTCCCCAGTAAGTCCAGCCTTGGGGGTTCTCCAGCTTCAT
TTTTTTAAGAGTGAGGATAATAACACTGAGGACCTGAAAGTGACAATAACAAAGGCTGGC
CGAAAGGATGATTCCACTTTGTGTTGTTGGCGGCATTCAACAACAGAAGTGTCCTGTCAG
AATCAGGAATATTTGTTTGTGTATGGGGGTCGAAGCGTGGTGGAACCTGTACTAAGTGAC
TGGCATTTCCTCCATGTAGGGACAATGGCTTGGGTCAGGATCCCAGTGGAGGGAGAAGTA
CCTGAAGCCCGGCATTCTCACAGTGCCTGCACTTGGCAAGGGGGAGCCCTTATTGCTGGA
GGTCTCGGGGCTTCTGAGGAGCCATTGAACTCTGTGCTCTTTCTGAGACCAATCTCTTGT
GGATTCCTCTGGGAGTCAGTAGACATCCAGCCTCCCATTACCCCAAGGTACTCCCACACA
GCTCATGTGCTCAATGGAAAGCTGTTACTGGTTGGAGGGATCTGGATTCATTCCTCCTCA
TTTCCTGGAGTGACTGTGATCAATTTGACTACAGGATTGAGCTCTGAGTATCAGATTGAC
ACAACATATGTGCCATGGCCATTAATGTTACACAACCATACTAGTATCCTTCTTCCTGAA
GAGCAACAGCTCCTGCTCCTTGGAGGTGGTGGGAACTGCTTTTCCTTTGGTACCTACTTC
AACCCCCATACAGTCACATTAGACCTTTCTTCCTTAAGTGCTGGGCAGTAA

# Drug_Target_4_General_Function:
Involved in methyltransferase activity

# Drug_Target_4_General_References:
10600115	De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, Goris J: Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry. 1999 Dec 14;38(50):16539-47.
12853982	Ng CC, Arakawa H, Fukuda S, Kondoh H, Nakamura Y: p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. Oncogene. 2003 Jul 10;22(28):4449-58.
9628581	Nagase T, Ishikawa K, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 1998 Feb 28;5(1):31-9.

# Drug_Target_4_HGNC_ID:
HGNC:17558

# Drug_Target_4_HPRD_ID:
17267

# Drug_Target_4_ID:
675

# Drug_Target_4_Locus:
15q15.3

# Drug_Target_4_Molecular_Weight:
75603

# Drug_Target_4_Name:
Leucine carboxyl methyltransferase 2

# Drug_Target_4_Number_of_Residues:
686

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF04072	LCM
PF07646	Kelch_2

# Drug_Target_4_Protein_Sequence:
>Leucine carboxyl methyltransferase 2
MGPRSRERRAGAVQNTNDSSALSKRSLAARGYVQDPFAALLVPGAARRAPLIHRGYYVRA
RAVRHCVRAFLEQIGAPQAALRAQILSLGAGFDSLYFRLKTAGRLARAAVWEVDFPDVAR
RKAERIGETPELCALTGPFERGEPASALCFESADYCILGLDLRQLQRVEEALGAAGLDAA
SPTLLLAEAVLTYLEPESAAALIAWAAQRFPNALFVVYEQMRPQDAFGQFMLQHFRQLNS
PLHGLERFPDVEAQRRRFLQAGWTACGAVDMNEFYHCFLPAEERRRVENIEPFDEFEEWH
LKCAHYFILAASRGDTLSHTLVFPSSEAFPRVNPASPSGVFPASVVSSEGQVPNLKRYGH
ASVFLSPDVILSAGGFGEQEGRHCRVSQFHLLSRDCDSEWKGSQIGSCGTGVQWDGRLYH
TMTRLSESRVLVLGGRLSPVSPALGVLQLHFFKSEDNNTEDLKVTITKAGRKDDSTLCCW
RHSTTEVSCQNQEYLFVYGGRSVVEPVLSDWHFLHVGTMAWVRIPVEGEVPEARHSHSAC
TWQGGALIAGGLGASEEPLNSVLFLRPISCGFLWESVDIQPPITPRYSHTAHVLNGKLLL
VGGIWIHSSSFPGVTVINLTTGLSSEYQIDTTYVPWPLMLHNHTSILLPEEQQLLLLGGG
GNCFSFGTYFNPHTVTLDLSSLSAGQ

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
May methylate the carboxyl group of leucine residues to form alpha-leucine ester residues

# Drug_Target_4_SwissProt_ID:
O60294

# Drug_Target_4_SwissProt_Name:
LCMT2_HUMAN

# Drug_Target_4_Synonyms:
EC 2.1.1.-
p21WAF1/CIP1 promoter-interacting protein
tRNA wybutosine-synthesizing protein 4 homolog

# Drug_Target_4_Theoretical_pI:
6.71

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
LCMT1

# Drug_Target_5_GenBank_ID_Gene:
AF037601

# Drug_Target_5_GenBank_ID_Protein:
6580758

# Drug_Target_5_GeneCard_ID:
LCMT1

# Drug_Target_5_Gene_Name:
LCMT1

# Drug_Target_5_Gene_Sequence:
>1005 bp
ATGGCCACTAGGCAGAGGGAATCCTCTATCACCTCCTGCTGTTCCACCTCGAGCTGCGAC
GCAGACGACGAGGGCGTGCGCGGCACCTGCGAAGATGCTTCCCTGTGCAAGAGGTTTGCA
GTAAGCATTGGCTACTGGCATGACCCTTACATACAGCACTTTGTGAGACTGTCTAAAGAG
AGGAAAGCCCCTGAAATCAACAGAGGATATTTTGCTCGAGTCCATGGTGTCAGTCAGCTT
ATAAAGGCATTTCTACGGAAGACAGAATGTCATTGTCAAATTGTCAACCTTGGGGCAGGC
ATGGATACCACCTTCTGGAGATTAAAGGATGAAGATCTTCTCCCAAGTAAATATTTTGAG
GTTGACTTTCCAATGATTGTCACGAGAAAGCTGCACAGTATCAAATGCAAGCCTCCCCTA
TCCAGCCCCATTCTAGAACTGCATTCAGAGGACACACTTCAAATGGATGGACACATACTG
GATTCAAAGAGATATGCCGTTATTGGAGCAGATCTCCGAGACCTGTCTGAACTGGAAGAG
AAGCTAAAGAAATGTAACATGAATACACAATTGCCAACACTCCTGATAGCTGAATGTGTG
CTGGTTTACATGACTCCAGAGCAGTCCGCAAACCTCCTGAAGTGGGCAGCCAACAGTTTT
GAGAGAGCCATGTTCATAAACTACGAACAGGTGAACATGGGTGATCGGTTTGGGCAGATC
ATGATTGAAAACCTGCGGAGACGCCAGTGTGAACTGGCGGGAGTGGAGACCTGCAAGTCA
TTAGAGTCACAGAAAGAACGGCTCCTGTCGAATGGGTGGGAAACAGCATCGGCCGTCGAC
ATGATGGAGTTGTACAACAGGTTACCTCGAGCTGAAGTGAGCAGGATAGAATCACTTGAA
TTCCTGGATGAAATGGACGTGCTGGAGCAGCTCAATGCGCATTACTGCCTTTGCTGGGCA
ACCAAAGGAGGAAATGAGCTTGGGCTGAAGGAGATAACTTATTAA

# Drug_Target_5_General_Function:
Involved in C-terminal protein carboxyl methyltransferase activity

# Drug_Target_5_General_References:
10600115	De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, Goris J: Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry. 1999 Dec 14;38(50):16539-47.
10810093	Lai CH, Chou CY, Ch'ang LY, Liu CS, Lin W: Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res. 2000 May;10(5):703-13.

# Drug_Target_5_HGNC_ID:
HGNC:17557

# Drug_Target_5_HPRD_ID:
17266

# Drug_Target_5_ID:
501

# Drug_Target_5_Locus:
16p12.3-16p12.1

# Drug_Target_5_Molecular_Weight:
38380

# Drug_Target_5_Name:
Leucine carboxyl methyltransferase 1

# Drug_Target_5_Number_of_Residues:
334

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF04072	LCM

# Drug_Target_5_Protein_Sequence:
>Leucine carboxyl methyltransferase 1
MATRQRESSITSCCSTSSCDADDEGVRGTCEDASLCKRFAVSIGYWHDPYIQHFVRLSKE
RKAPEINRGYFARVHGVSQLIKAFLRKTECHCQIVNLGAGMDTTFWRLKDEDLLPSKYFE
VDFPMIVTRKLHSIKCKPPLSSPILELHSEDTLQMDGHILDSKRYAVIGADLRDLSELEE
KLKKCNMNTQLPTLLIAECVLVYMTPEQSANLLKWAANSFERAMFINYEQVNMGDRFGQI
MIENLRRRQCDLAGVETCKSLESQKERLLSNGWETASAVDMMELYNRLPRAEVSRIESLE
FLDEMELLEQLMRHYCLCWATKGGNELGLKEITY

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Methylates the carboxyl group of the C-terminal leucine residue of protein phosphatase 2A catalytic subunits (PPP2CA) to form alpha-leucine ester residues

# Drug_Target_5_SwissProt_ID:
Q9UIC8

# Drug_Target_5_SwissProt_Name:
LCMT1_HUMAN

# Drug_Target_5_Synonyms:
EC 2.1.1.-
Protein-leucine O- methyltransferase

# Drug_Target_5_Theoretical_pI:
5.91

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
16774921	Hsu JL, Rho SB, Vannella KM, Martinis SA: Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. J Biol Chem. 2006 Aug 11;281(32):23075-82. Epub 2006 Jun 14.
16955236	Dohm JC, Vingron M, Staub E: Horizontal gene transfer in aminoacyl-tRNA synthetases including leucine-specific subtypes. J Mol Evol. 2006 Oct;63(4):437-47. Epub 2006 Sep 4.
16956879	Karkhanis VA, Boniecki MT, Poruri K, Martinis SA: A viable amino acid editing activity in the leucyl-tRNA synthetase CP1-splicing domain is not required in the yeast mitochondria. J Biol Chem. 2006 Nov 3;281(44):33217-25. Epub 2006 Sep 6.
17144674	Ma JJ, Zhao MW, Wang ED: Split leucine-specific domain of leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus. Biochemistry. 2006 Dec 12;45(49):14809-16.
17407263	Vu MT, Martinis SA: A unique insert of leucyl-tRNA synthetase is required for aminoacylation and not amino acid editing. Biochemistry. 2007 May 1;46(17):5170-6. Epub 2007 Apr 4.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
LARS

# Drug_Target_6_GenBank_ID_Gene:
D84223

# Drug_Target_6_GenBank_ID_Protein:
7804450

# Drug_Target_6_GeneCard_ID:
LARS

# Drug_Target_6_Gene_Name:
LARS

# Drug_Target_6_Gene_Sequence:
>3531 bp
ATGGCGGAAAGAAAAGGAACAGCCAAAGTGGACTTTTTGAAGAAGATTGAGAAAGAAATC
CAACAGAAATGGGATACTGAGAGAGTGTTTGAGGTCAATGCATCTAATTTAGAGAAACAG
ACCAGCAAGGGCAAGTATTTTGTAACCTTCCCATATCCATATATGAATGGACGCCTTCAT
TTGGGACACACGTTTTCTTTATCCAAATGTGAGTTTGCTGTAGGGTACCAGCGATTGAAA
GGAAAATGTTGTCTGTTTCCCTTTGGCCTGCACTGTACTGGAATGCCTATTAAGGCATGT
GCTGATAAGTTGAAAAGAGAAATAGAGCTGTATGGTTGCCCCCCTGATTTTCCAGATGAA
GAAGAGGAAGAGGAAGAAACCAGTGTTAAAACAGAAGATATAATAATTAAGGATAAAGCT
AAAGGAAAAAAGAGTAAAGCTGCTGCTAAAGCTGGATCTTCTAAATACCAGTGGGGCATT
ATGAAATCCCTTGGCCTGTCTGATGAAGAGATAGTAAAATTTTCTGAAGCAGAACATTGG
CTTGATTATTTCCCGCCACTGGCTATTCAGGATTTAAAAAGAATGGGTTTGAAGGTAGAC
TGGCGTCGTTCCTTCATCACCACTGATGTTAATCCTTACTATGATTCATTTGTCAGATGG
CAATTTTTAACATTAAGAGAAAGAAACAAAATTAAATTTGGGAAGCGGTATACAATTTAC
TCTCCGAAAGATGGACAGCCTTGCATGGATCATGATAGACAAACTGGAGAGGGTGTTGGA
CCTCAGGAATATACTTTACTCAAATTGAAGGCGCTTGAGCCATACCCATCTAAATTAAGT
GGCCTGAAAGGTAAAAATATTTTCTTGGTGGCTGCTACTCTCAGACCTGAGACCATGTTT
GGGCAGACAAATTGTTGGGTTCGTCCTGATATGAAGTACATTGGATTTGAGACGGTGAAT
GGTGATATATTCATCTGTACCCAAAAAGCAGCCAGGAATATGTCATACCAGGGCTTTACC
AAAGACAATGGCGTGGTGCCTGTTGTTAAGGAATTAATGGGGGAGGAAATTCTTGGTGCA
TCACTTTCTGCACCTTTAACATCATACAAGGTGATCTATGTTCTCCCAATGCTAACTATT
AAGGAGGATAAAGGCACTGGTGTGGTTACAAGTGTTCCTTCCGACTCCCCTGATGATATT
GCTGCCCTCAGAGACTTGAAGAAAAAGCAAGCCTTACGAGCAAAATATGGAATTAGAGAT
GACATGGTCTTGCCATTTGAGCCGGTGCCAGTCATTGAAATCCCAGGTTTTGGAAATCTT
TCTGCTGTAACCATTTGTGATGAGTTGAAAATTCAGAGCCAGAATGACCGGGAAAAACTT
GCAGAAGCAAAGGAGAAGATATATCTAAAAGGATTTTATGAGGGTATCATGTTGGTGGAT
GGATTTAAAGGACAGAAGGTTCAAGATGTAAAGAAGACTATTCAGAAAAAGATGATTGAC
GCTGGAGATGCACTTATTTACATGGAACCAGAGAAACAAGTGATGTCCAGGTCGTCAGAT
GAATGTGTTGTGGCTCTGTGTGACCAGTGGTACTTGGATTATGGAGAAGAGAATTGGAAG
AAACAGACATCTCAGTGCTTGAAGAACCTGGAAACATTCTGTGAGGAGACCAGGAGGAAT
TTTGAAGCCACCTTAGGTTGGCTACAAGAACATGCTTGCTCAAGAACTTATGGTCTAGGC
ACTCACCTGCCTTGGGATGAGCAGTGGCTGATTGAATCACTTTCTGACTCCACTATTTAC
ATGGCATTTTACACAGTTGCACACCTATTGCAGGGGGGTAACTTGCATGGACAGGCAGAG
TCTCCGCTGGGCATTAGACCGCAACAGATGACCAAGGAAGTTTGGGATTATGTTTTCTTC
AAGGAGGCTCCATTTCCTAAGACTCAGATTGCAAAGGAAAAATTAGATCAGTTAAAGCAG
GAGTTTGAATTCTGGTATCCTGTTGATCTTCGCGTCTCTGGCAAGGATCTTGTTCCAAAT
CATCTTTCATATTACCTTTATAATCATGTGGCTATGTGGCCGGAACAAAGTGATAAATGG
CCTACAGCTGTGAGAGCAAATGGACATCTCCTCCTGAACTCTGAGAAGATGTCAAAATCC
ACAGGCAACTTCCTCACTTTGACCCAAGCTATTGACAAATTTTCAGCAGATGGAATGCGT
TTGGCTCTGGCTGATGCTGGTGACACTGTAGAAGATGCCAACTTTGTGGAAGCCATGGCA
GATGCAGGTATTCTCCGTCTGTACACCTGGGTAGAGTGGGTGAAAGAAATGGTTGCCAAC
TGGGACAGCCTAAGAAGTGGTCCTGCCAGCACTTTCAATGATAGAGTTTTTGCCAGTGAA
TTGAATGCAGGAATTATAAAAACAGATCAAAACTATGAAAAGATGATGTTTAAAGAAGCT
TTGAAAACAGGGTTTTTTGAGTTTCAGGCCGCAAAAGATAAGTACCGTGAATTGGCTGTG
GAAGGGATGCACAGAGAACTTGTGTTCCGGTTTATTGAAGTTCAGACACTTCTCCTCGCT
CCATTCTGTCCACATTTGTGTGAGCACATCTGGACACTCCTGGGAAAGCCTGACTCAATT
ATGAATGCTTCATGGCCTGTGGCAGGTCCTGTGGATGAAGTTTTAATACACTCCTCACAG
TATCTTATGGAAGTAACACATGACCTTAGACTACGACTCAAGAACTATATGATGCCAGCT
AAAGGGAAGAAGACCGACAAACAACCCCTGCAGAAGCCCTCACATTGCACCATCTATGTG
GCAAAGAACTATCCACCTTGGCAACATACCACCCTGTCTGTTCTACGTAAACACTTTGAG
GCCAATAACGGAAAACTGCCTGACAACAAAGTCATTGCTAGTGAACTAGGCAGTATGCCA
GAACTGAAGAAATACATGAAGAAAGTCATGCCATTTGTTGCCATGATTAAGGAAAATCTG
GAGAAGATGGGGCCTCGTATTCTGGATTTGCAATTAGAATTTGATGAAAAGGCTGTGCTT
ATGGAGAATATAGTCTATCTGACTAATTCGCTTGAGCTAGAACACATAGAAGTCAAGTTT
GCCTCCGAAGCAGAAGATAAAATCAGGGAAGACTGCTGTCCTGGGAAACCACTTAATGTT
TTTAGAATAGAACCTGGTGTGTCCGTTTCTCTGGTGAATCCCCAGCCATCCAATGGCCAC
TTCTCAACCAAAATTGAAATCAAGCAAGGAGATAACTGTGATTCCATAATCAGGCGTTTA
ATGAAAATGAATCGAGGAATTAAAGACCTTTCCAAAGTGAAACTGATGAGATTTGATGAT
CCACTGTTGGGGCCTCGACGAGTTCCTGTCCTGGGAAAGGAGTACACCGAGAAGACCCCC
ATTTCTGAGCATGCTGTTTTCAATGTGGACCTCATGAGCAAGAAAATTCATCTGACTGAG
AATGGGATAAGGGTGGATATTGGCGATACAATAATCTATCTGGTTCATTAA

# Drug_Target_6_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_6_General_References:
10718198	Nagase T, Kikuno R, Ishikawa KI, Hirosawa M, Ohara O: Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2000 Feb 28;7(1):65-73.

# Drug_Target_6_HGNC_ID:
HGNC:6512

# Drug_Target_6_HPRD_ID:
01042

# Drug_Target_6_ID:
846

# Drug_Target_6_Locus:
5q32

# Drug_Target_6_Molecular_Weight:
134468

# Drug_Target_6_Name:
Leucyl-tRNA synthetase, cytoplasmic

# Drug_Target_6_Number_of_Residues:
1176

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01406	tRNA-synt_1e
PF08264	Anticodon_1

# Drug_Target_6_Protein_Sequence:
>Leucyl-tRNA synthetase, cytoplasmic
MAERKGTAKVDFLKKIEKEIQQKWDTERVFEVNASNLEKQTSKGKYFVTFPYPYMNGRLH
LGHTFSLSKCEFAVGYQRLKGKCCLFPFGLHCTGMPIKACADKLKREIELYGCPPDFPDE
EEEEEETSVKTEDIIIKDKAKGKKSKAAAKAGSSKYQWGIMKSLGLSDEEIVKFSEAEHW
LDYFPPLAIQDLKRMGLKVDWRRSFITTDVNPYYDSFVRWQFLTLRERNKIKFGKRYTIY
SPKDGQPCMDHDRQTGEGVGPQEYTLLKLKVLEPYPSKLSGLKGKNIFLVAATLRPETMF
GQTNCWVRPDMKYIGFETVNGDIFICTQKAARNMSYQGFTKDNGVVPVVKELMGEEILGA
SLSAPLTSYKVIYVLPMLTIKEDKGTGVVTSVPSDSPDDIAALRDLKKKQALRAKYGIRD
DMVLPFEPVPVIEIPGFGNLSAVTICDELKIQSQNDREKLAEAKEKIYLKGFYEGIMLVD
GFKGQKVQDVKKTIQKKMIDAGDALIYMEPEKQVMSRSSDECVVALCDQWYLDYGEENWK
KQTSQCLKNLETFCEETRRNFEATLGWLQEHACSRTYGLGTHLPWDEQWLIESLSDSTIY
MAFYTVAHLLQGGNLHGQAESPLGIRPQQMTKEVWDYVFFKEAPFPKTQIAKEKLDQLKQ
EFEFWYPVDLRVSGKDLVPNHLSYYLYNHVAMWPEQSDKWPTAVRANGHLLLNSEKMSKS
TGNFLTLTQAIDKFSADGMRLALADAGDTVEDANFVEAMADAGILRLYTWVEWVKEMVAN
WDSLRSGPASTFNDRVFASELNAGIIKTDQNYEKMMFKEALKTGFFEFQAAKDKYRELAV
EGMHRELVFRFIEVQTLLLAPFCPHLCEHIWTLLGKPDSIMNASWPVAGPVNEVLIHSSQ
YLMEVTHDLRLRLKNYMMPAKGKKTDKQPLQKPSHCTIYVAKNYPPWQHTTLSVLRKHFE
ANNGKLPDNKVIASELGSMPELKKYMKKVMPFVAMIKENLEKMGPRILDLQLEFDEKAVL
MENIVYLTNSLELEHIEVKFASEAEDKIREDCCPGKPLNVFRIEPGVSVSLVNPQPSNGH
FSTKIEIRQGDNCDSIIRRLMKMNRGIKDLSKVKLMRFDDPLLGPRRVPVLGKEYTEKTP
ISEHAVFNVDLMSKKIHLTENGIRVDIGDTIIYLVH

# Drug_Target_6_Reaction:
ATP + L-leucine + tRNALeu = AMP + diphosphate + L-leucyl-tRNALeu

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
Q9P2J5

# Drug_Target_6_SwissProt_Name:
SYLC_HUMAN

# Drug_Target_6_Synonyms:
EC 6.1.1.4
LeuRS
Leucine--tRNA ligase

# Drug_Target_6_Theoretical_pI:
7.31

# Drug_Target_6_Transmembrane_Regions:
None

#END_DRUGCARD DB00149
